Recently, the American research university Loyola (Loyola University Chicago) School of Medicine showed that a treatment for leukemia drug dasatinib imatinib shown to skin cancer, breast cancer and other types of cancer have a therapeutic effect.
Recently, the American research university Loyola (Loyola University Chicago) School of Medicine showed that a treatment for leukemia drug dasatinib (Dasatinib, trade name Sprycel, CEDAR tournament) shows skin cancer, breast cancer and Some other types of cancer have a therapeutic effect.
Dasatinib those by inhibiting the growth of tumor cells indiscriminately to treat leukemia.
However, the researchers found that when using dasatinib treatment of other types of cancer cells, it can be another different mechanisms of action to treat the tumor: the tumor cells together and prevent tumor cell migration. If the tumor cells lose the ability to migrate, then the cancer cells can not spread to other tissues and organs.
Dr. Mitchell Denning and his colleagues discovered the molecular mechanism of this cell adhesion between the relevant findings published online in the near future “molecular carcinogenesis” magazine.
It is understood that when the United States hundreds of dasatinib by Myers Squibb has developed and has been approved by the FDA for the treatment of certain types of leukemia, suitable for including imatinib mesylate treatment options, including drug-resistant or intolerant Chronic myeloid leukemia (CML) all of disease (chronic phase, accelerated phase, lymphocytes and myeloid blast phase CML) in adult patients, and Philadelphia for the past treatment of drug resistant or intolerant chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in adult patients.
Dasatinib is an oral multi-tyrosine kinase inhibitor, a protein that can be targeted to accelerate action on cancer cell proliferation, called BCR-ABL’s. And Fyn protein BCR-ABL protein is very similar, Fyn other malignancies, including breast cancer, brain cancer, pancreatic cancer, skin cancer, head and neck cancer are found. Between Fyn and related cell adhesion and cell migration.
In the study, tannins and his colleagues found that dasatinib to cause the accumulation of tumor cells, but also can prevent its migration. Moreover, in breast cancer cells have similar findings. Although dasatinib not degrade Fyn, but can inhibit the activity of Fyn. Meanwhile, the researchers found that dasatinib to reduce the number of tumor cells in mice skin cancer and reduce tumor volume.
Tannins introduction, clinical trials are underway to test dasatinib melanoma, prostate cancer, pancreatic cancer, endometrial cancer, gastrointestinal stromal cancer, ovarian cancer, multiple myeloma, Hodgkin’s Therapeutic effect of lymphoma and acute lymphocytic leukemia. “We believe that dasatinib to apply in many different types of tumors.” Denning said.